The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars available for patients — and realizing “tremendous savings” — that should be adopted in the United States, according to an analysis.
“With exception of the Kaiser Permanente health system and U.S. Veterans Affairs, biosimilars have not been widely adopted in the United States, due to patent issues — use patents are relevant only in the United States — lawsuits — such as the recently settled Pfizer versus Janssen lawsuit over the former’s